<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04473989</url>
  </required_header>
  <id_info>
    <org_study_id>M2020207</org_study_id>
    <nct_id>NCT04473989</nct_id>
  </id_info>
  <brief_title>Weekly Use of Teriparatide to Accelerate Healing of Distal Radius Fracture</brief_title>
  <official_title>The Effect of Weekly Injection of Teriparatide on the Healing of Distal Radius Fracture in a Double-blind, Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effect of weekly dosing strategy on fracture
      healing.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The median time of radiographic healing</measure>
    <time_frame>0-14 weeks</time_frame>
    <description>A score of 13 by Modified Radiographic Union Scale for Tibia fractures (mRUST) scoring system would provide a confident assessment of union</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient-Rated Wrist Evaluation</measure>
    <time_frame>0, 4, 6, 8, 10, 12, 14 and 16 weeks</time_frame>
    <description>A 15-item questionnaire(PRWE) that rates wrist-related pain and disability in functional activities. The scores range from 0 (no disability) to 100 (severest disability).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grip strength</measure>
    <time_frame>6, 8, 10, 12, 14, and 16 weeks</time_frame>
    <description>Grip strength will be assessed by a dynamometer.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Colles' Fracture</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Injection product without active teriparatide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTH 40ug/w</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection product with active teriparatide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant teriparatide for injection</intervention_name>
    <description>weekly subcutaneous administration of 40 ug</description>
    <arm_group_label>PTH 40ug/w</arm_group_label>
    <other_name>Xinfutai</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>weekly subcutaneous administration of 40 ug</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Xinfutai placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Postmenopausal women aged 45-75 (at least 2 years after menopause)

          2. With primary osteoporosis

          3. Patients with Colles fractures with a fracture time of no more than 7 days

          4. conservative treatment after fracture (closed reduction and immobilization)

          5. no multiple fractures

          6. Informed well and agree to participate in this clinical trial

        Exclusion Criteria:

          1. Combine other physical diseases, including diabetes, severe hypertension, autoimmune
             diseases, heart, liver and kidney diseases, malignant tumors, mental illnesses, and
             other diseases that doctors believe may affect the healing process.

          2. In addition to primary osteoporosis, any disease affecting bone metabolism or
             treatment response, including serum PTH&gt;65pg/ml, 25-hydroxyvitamin D&lt;20ng/ml, alkaline
             phosphatase&gt;135U/L, history of bone tumor, Paget disease, history of radiotherapy

          3. The fracture site has a history of trauma or surgery, affecting the function of the
             wrist or forearm

          4. Those who are allergic to PTH or any excipients

          5. Currently receiving anti-osteoporosis treatment or receiving other anti-osteoporosis
             treatment during the trial

          6. Contraindication of teriparatide including hyperparathyroidism, severe renal
             insufficiency, hypercalcemia, etc.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Postmenopausal women</gender_description>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chunli Song, M.D.; Ph. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Junxiong Zhu, M.D.</last_name>
    <phone>+86 18801238160</phone>
    <email>zhujunxiong@bjmu.edu.cn</email>
  </overall_contact>
  <reference>
    <citation>Aspenberg P, Genant HK, Johansson T, Nino AJ, See K, Krohn K, García-Hernández PA, Recknor CP, Einhorn TA, Dalsky GP, Mitlak BH, Fierlinger A, Lakshmanan MC. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010 Feb;25(2):404-14. doi: 10.1359/jbmr.090731.</citation>
    <PMID>19594305</PMID>
  </reference>
  <reference>
    <citation>Ebata S, Takahashi J, Hasegawa T, Mukaiyama K, Isogai Y, Ohba T, Shibata Y, Ojima T, Yamagata Z, Matsuyama Y, Haro H. Role of Weekly Teriparatide Administration in Osseous Union Enhancement within Six Months After Posterior or Transforaminal Lumbar Interbody Fusion for Osteoporosis-Associated Lumbar Degenerative Disorders: A Multicenter, Prospective Randomized Study. J Bone Joint Surg Am. 2017 Mar 1;99(5):365-372. doi: 10.2106/JBJS.16.00230.</citation>
    <PMID>28244906</PMID>
  </reference>
  <reference>
    <citation>Zhang W, Zhu J, Ma T, Liu C, Hai B, Du G, Wang H, Li N, Leng H, Xu Y, Song C. Comparison of the effects of once-weekly and once-daily rhPTH (1-34) injections on promoting fracture healing in rodents. J Orthop Res. 2018 Apr;36(4):1145-1152. doi: 10.1002/jor.23750. Epub 2017 Nov 20.</citation>
    <PMID>28960481</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 12, 2020</study_first_submitted>
  <study_first_submitted_qc>July 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2020</study_first_posted>
  <last_update_submitted>July 12, 2020</last_update_submitted>
  <last_update_submitted_qc>July 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colles' Fracture</mesh_term>
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Radius Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

